- Home
- RNP vs XNCR Comparison
RNP vs XNCR Comparison
Compare RNP & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RNP | XNCR |
|---|---|---|
| Founded | 2003 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 959.9M | 928.3M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | RNP | XNCR |
|---|---|---|
| Price | $20.00 | $13.19 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $22.78 |
| AVG Volume (30 Days) | 117.6K | ★ 725.1K |
| Earning Date | 01-01-0001 | 02-26-2026 |
| Dividend Yield | ★ 7.94% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $150,132,000.00 |
| Revenue This Year | N/A | $18.68 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 38.16 |
| 52 Week Low | $15.52 | $6.92 |
| 52 Week High | $21.27 | $20.09 |
Technical Indicators
Market Signals| Indicator | RNP | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 46.23 | 40.80 |
| Support Level | $19.94 | $12.50 |
| Resistance Level | $20.13 | $13.75 |
| Average True Range (ATR) | 0.21 | 0.77 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 9.54 | 25.75 |
Price Performance
Historical ComparisonAbout RNP Cohen & Steers REIT and Preferred and Income Fund Inc.
Cohen & Steers REIT and Preferred Income Fund Inc is a diversified, closed-ended investment management fund. Its investment objective is to provide high current income with capital appreciation as its secondary objective. The Fund invests at least its total assets in common stocks issued by real estate investment trusts (REITs) and preferred securities under normal circumstances.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.